Drs Sigrid Marie Kraggerud, Christina H°i-Hansen and Sharmini Alagaratnam publish in Endrocrine Reviews, the highest ranked journal in the category of Endocrinology and metabolism with IF of 19.9.
In a comprehensive review the Lothe group together with colleagues from University of Copenhagen (Rigshospitalet), Dr. Ewa Rajpert-Dde Meyts group, revisit the total literature on molecular biology of germ cell tumors of the ovary. The molecular features of the mOGCTs underline their similarity to pluripotent precursor cells (primordial germ cells, PGCs) and other stem cells. This similarity combined with the process of ovary development, explain why mOGCTs present so early in life, and with greater histological complexity, than most somatic solid tumors.
Sharmini Alagaratnam has worked both for the Norwegian Research Council’s Program for Stem Cell Research, and the Cancer Stem Cell Innovation Center CAST, on a project to identify malignancy genes in stem cells. Part of this work has recently been published in the journal Stem Cells and Development, and represents the first direct comparison of gene expression in embryonic stem cells and their malignant counterpart, embryonal carcinoma, cultured under identical conditions. This was a collaborative study between the Molecular Genetics and the Genome Biology groups at the Department of Cancer Prevention.
A gene signature distinguishing the two cell types was identified, which included a number of cancer relevant and pluripotency genes. NR5A2 is an especially intriguing candidate given its role in the WNT-signalling pathway, which is often disrupted in cancer, and particularly so in colorectal cancer.
Tankyrases 1 and 2 (TNKS1/2) are promising pharmacological biotargets with possible applications for the development of novel anticancer therapeutics. A focused structure-activity relationship study was conducted based on the tankyrase inhibitor JW74 (1).
Fra science fiction til Nobelpris- kronikk i Aftenposten
40 millioner til OUS-ledet kreftforskning
Et nasjonalt kreftforskningsprosjekt ledet ved Oslo universitetssykehus har fått 40 millioner kroner fra Forskningsrådet. Prosjektet er det eneste medisinske prosjektet som fikk støtte under den siste tildelingen fra BIOTEK2021, Forskningsrådets program for bioteknologi. Ola Myklebost, seniorforsker ved OUS, er leder for Kreftgenomikkprosjektet.
The Continuing Professional Development centre of the Oxford University Department for Continuing Education run a short course on Stem Cells
5-7 December 2012 Twenty lecture and discussion sessions which bring together eighteen of the leading experts in the field to explore this cutting-edge technology. Note, this is a two-day course held over three days - from lunchtime on Wednesday until lunchtime on Friday. Led by Dr Paul Fairchild, Co-Director, Oxford Stem Cell Institute, Sir William Dunn School of Pathology, University of Oxford
5-7 December 2012
Twenty lecture and discussion sessions which bring together eighteen of the leading experts in the field to explore this cutting-edge technology. Note, this is a two-day course held over three days - from lunchtime on Wednesday until lunchtime on Friday.
Led by Dr Paul Fairchild, Co-Director, Oxford Stem Cell Institute, Sir William Dunn School of Pathology, University of Oxford
SFI-CAST Annual Report 2011
Oxford Gene Technology Signs Licensing Deal for Colorectal Cancer Biomarkers
Based on development of biomarkers suitable for early detection of colorectal cancer in the groups of Lothe and Skotheim, Inven2, on behalf of Oslo University Hospital, has recently signed a lisence agreement with Oxford Gene Technology.